NCT03275051View on ClinicalTrials.gov

Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL)

NAActive, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 4, 2017

Primary Completion Date

December 1, 2025

Study Completion Date

June 1, 2026

Conditions
Beta Thalassaemia
Interventions
OTHER

Safety and Efficacy assessments

Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.

Trial Locations (1)

20132

Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET), Milan

All Listed Sponsors
collaborator

Telethon Institute for Gene Therapy (OSR-TIGET)

UNKNOWN

lead

IRCCS San Raffaele

OTHER

NCT03275051 - Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL) | Biotech Hunter | Biotech Hunter